Raising the Bar: Improving Antimicrobial Resistance Detection by Clinical Laboratories by Ensuring Use of Current Breakpoints.

antimicrobial resistance breakpoints laboratory testing susceptibility testing

Journal

Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045

Informations de publication

Date de publication:
Mar 2022
Historique:
received: 27 12 2021
accepted: 07 01 2022
entrez: 11 2 2022
pubmed: 12 2 2022
medline: 12 2 2022
Statut: epublish

Résumé

Antimicrobial resistance (AMR) is a pressing global challenge detected by antimicrobial susceptibility testing (AST) performed by clinical laboratories. AST results are interpreted using clinical breakpoints, which are updated to enable accurate detection of new and emerging AMR. Laboratories that do not apply up-to-date breakpoints impede global efforts to address the AMR crisis, but the extent of this practice is poorly understood. A total of 1490 clinical laboratories participating in a College of American Pathologists proficiency testing survey for bacterial cultures were queried to determine use of obsolete breakpoints. Between 37.9% and 70.5% of US laboratories reported using obsolete breakpoints for the antimicrobials that were queried. In contrast, only 17.7%-43.7% of international laboratories reported using obsolete breakpoints ( These data demonstrate a significant gap in the ability to detect AMR in the US, and to a lesser extent internationally. Improved application of current breakpoints by clinical laboratories will require combined action from regulatory agencies, laboratory accreditation groups, and device manufacturers.

Sections du résumé

BACKGROUND BACKGROUND
Antimicrobial resistance (AMR) is a pressing global challenge detected by antimicrobial susceptibility testing (AST) performed by clinical laboratories. AST results are interpreted using clinical breakpoints, which are updated to enable accurate detection of new and emerging AMR. Laboratories that do not apply up-to-date breakpoints impede global efforts to address the AMR crisis, but the extent of this practice is poorly understood.
METHODS METHODS
A total of 1490 clinical laboratories participating in a College of American Pathologists proficiency testing survey for bacterial cultures were queried to determine use of obsolete breakpoints.
RESULTS RESULTS
Between 37.9% and 70.5% of US laboratories reported using obsolete breakpoints for the antimicrobials that were queried. In contrast, only 17.7%-43.7% of international laboratories reported using obsolete breakpoints (
CONCLUSIONS CONCLUSIONS
These data demonstrate a significant gap in the ability to detect AMR in the US, and to a lesser extent internationally. Improved application of current breakpoints by clinical laboratories will require combined action from regulatory agencies, laboratory accreditation groups, and device manufacturers.

Identifiants

pubmed: 35146049
doi: 10.1093/ofid/ofac007
pii: ofac007
pmc: PMC8826219
doi:

Types de publication

Journal Article

Langues

eng

Pagination

ofac007

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Références

J Clin Microbiol. 2020 Mar 25;58(4):
pubmed: 32213574
J Clin Microbiol. 2019 May 24;57(6):
pubmed: 30971460
Clin Infect Dis. 2018 Mar 19;66(7):1061-1067
pubmed: 29099915
Antimicrob Agents Chemother. 2020 Oct 20;64(11):
pubmed: 32816693
J Pediatric Infect Dis Soc. 2012 Jun;1(2):166-8
pubmed: 26619172
J Clin Microbiol. 2015 Jan;53(1):201-5
pubmed: 25378572
Eur J Clin Microbiol Infect Dis. 2020 Jan;39(1):187-195
pubmed: 31679102
J Clin Microbiol. 2020 Mar 25;58(4):
pubmed: 32213579
Clin Infect Dis. 2016 Jul 1;63(1):83-8
pubmed: 27025822
Clin Infect Dis. 2020 Dec 17;71(10):2736-2743
pubmed: 32361747
Clin Infect Dis. 2013 May;56(9):1301-9
pubmed: 23334813
J Clin Microbiol. 2018 Apr 25;56(5):
pubmed: 29436415
J Clin Microbiol. 2020 Feb 24;58(3):
pubmed: 31915289
J Clin Microbiol. 2016 Nov;54(11):2757-2762
pubmed: 27582516
Clin Infect Dis. 2009 Dec 1;49(11):1749-55
pubmed: 19857164

Auteurs

Patricia J Simner (PJ)

Johns Hopkins Medical Institute, Baltimore, Maryland, USA.

Carol A Rauch (CA)

Vanderbilt University, Nashville, Tennessee, USA.

Isabella W Martin (IW)

Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.

Kaede V Sullivan (KV)

Temple University Hospital, Philadelphia, Pennsylvania, USA.

Daniel Rhoads (D)

Cleveland Clinic, Cleveland, Ohio, USA.

Robin Rolf (R)

College of American Pathologists, Chicago, Illinois, USA.

Rosemary She (R)

University of Southern California, Los Angeles, California, USA.

Rhona J Souers (RJ)

College of American Pathologists, Chicago, Illinois, USA.

Christina Wojewoda (C)

University of Vermont Medical Center, Burlington, Vermont, USA.

Romney M Humphries (RM)

Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Classifications MeSH